Nanoparticle-based vaccines: Opportunities and limitations. opportunities and limitations.

Keyphrases

• Nanoparticles 100%
• Nanoparticle-based Vaccine 100%
• Infectious Diseases 60%
• Delivery System 60%
• Vaccine Effectiveness 40%
• Antigen-presenting Cells 40%
• Human Use 40%
• Virus-like 20%
• Developing Countries 20%
• Lipids 20%
• Antibiotics 20%
• Immunosuppression 20%
• Pathogenicity 20%
• Physicochemical Properties 20%
• Vaccine Development 20%
• Economic Burden 20%
• Protective Immunity 20%
• Subunit Vaccine 20%
• Humoral Immune Response 20%
• Influenza 20%
• Smallpox 20%
• Vaccine Adjuvant 20%
• Proteolytic Degradation 20%
• Animal Use 20%
• Antigen Uptake 20%
• Hepatitis B 20%
• Immunization Strategy 20%
• Veterinary Use 20%
• Essential Needs 20%
• Live Attenuated 20%
• Attenuated Vaccine 20%
• Efficient Delivery 20%
• Vaccine Formulation 20%
• Cell-mediated Immune Response 20%
• Antigen Release 20%
• Adjuvant System 20%
• Non-metal 20%
• Antigen Processing 20%
• Degradation Control 20%
• Next-generation Vaccines 20%

Immunology and Microbiology

• Vaccine Efficacy 100%
• Antigen-Presenting Cell 100%
• Infectious Agent 50%
• Immunosuppression 50%
• Pathogenicity 50%
• Mycobacterium Bovis BCG 50%
• Subunit Vaccine 50%
• Humoral Immunity 50%
• Influenza 50%
• Adjuvant 50%
• Antigen Presentation 50%
• Virus-Like Particle 50%
• Hepatitis B 50%
• Smallpox 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Nanoparticle 100%
• Diseases 42%
• Vaccine Efficacy 28%
• Virus Like Agent 14%
• Antibiotics 14%
• Pathogenicity 14%
• Infectious Agent 14%
• Vaccine Development 14%
• Subunit Vaccine 14%
• Mycobacterium Bovis BCG 14%
• Smallpox 14%
• Attenuated Vaccine 14%
• Vaccine Adjuvant 14%
• Hepatitis B 14%